I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Enterobacteriaceae pathogens are the most commonly isolated Gram-negative bacteria identified in human blood samples. Once bloodstream infection occurs, these pathogens often result in major health problems, requiring a lengthy hospital stay, multiple antibiotic use, high medical expenses, and even death. A previous study\[[@ref1]\] showed that patients with Gram-negative bloodstream infections have more severe inflammatory reactions and clinical symptoms than patients with Gram-positive bloodstream infections. Due to poor regulations and inappropriate use of antibiotics, antimicrobial resistance (AMR) has become a major challenge, particularly within the last decade.

In this study, we evaluated the antimicrobial susceptibility profiles ofEnterobacteriaceae from blood samples with the goal of controlling AMR and improving the efficient utilization of antibiotics.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

Ethics committee approval was not required because we did not collect patient identifying information.

Clinical isolates {#sec2-2}
-----------------

All isolates obtained from blood samples were collected biennially from a cumulative total of 19 tertiary hospitals in mainland China over five consecutive 1-year periods between October 2004 and June 2014 (2004--2005, 2007--2008, 2009--2010, 2011--2012, and 2013--2014) and were then sent to the Institute of Clinical Pharmacology, Peking University First Hospital. These participating tertiary hospitals are located in 15 different provinces in China, and only one isolate per species per patient was collected to avoid repetitive counts in this study. Every strain to be tested was recovered and purified before the experiment to ensure the viability and purity of the bacteria. Bacterial suspensions were obtained by inoculation with 10^4^ CFU of each bacterium via a multipoint inoculator. All isolates were identified by standard methods used in clinical microbiology laboratories. All organisms were deemed clinically significant by local participant criteria.

Susceptibility testing {#sec2-3}
----------------------

*In vitro* susceptibilities to antimicrobial agents were identified by the agar dilution method, and susceptibility profiles were identified by the minimum inhibitory concentration (MIC) interpretative breakpoint criteria according to Clinical and Laboratory Standards Institute 2016 guidelines (CLSI 2016)\[[@ref2]\] or EUCAST 2016\[[@ref3]\] if CLSI 2016 did not provide the specific breakpoint. The double-disk synergy test was performed to identify ESBL-producing isolates among *Escherichia coli* and *Klebsiella pneumoniae*, as recommended by CLSI 2016.

Quality control {#sec2-4}
---------------

Quality control was performed using the reference strains *E. coli* ATCC 25922 and *E. coli* ATCC 35218 according to CLSI 2016. The following antibiotics were included: amoxicillin, amoxicillin-clavulanic acid (AMC), piperacillin, piperacillin-tazobactam (TZP), mezlocillin, mezlocillin-sulbactam (MSU), cefazolin, cefuroxime, ceftriaxone, cefotaxime, ceftazidime, cefoperazone, cefoperazone-sulbactam (CSL), cefepime, aztreonam, moxalactam, imipenem, meropenem, panipenem, ertapenem, gentamycin, amikacin, tetracycline, minocycline, tigecycline, ciprofloxacin, levofloxacin, nitrofurantoin, fosfomycin, polymyxin B, and colistin.

Statistical analysis {#sec2-5}
--------------------

Statistical tests were analyzed by Statistical Package for the Social Sciences 20.0 software (SPSS, Inc., Chicago, IL, USA). Enumeration data were presented as percentage values. Differences in susceptibility to antibiotics between groups were analyzed by Fisher\'s exact tests and Chi-square tests. Results with *P* \< 0.05 were considered statistically significant using two-tailed tests.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Distribution of Enterobacteriaceae pathogens {#sec2-6}
--------------------------------------------

Over five consecutive 1-year studies, a total of 2240 Enterobacteriaceae pathogens isolated from blood samples from 19 participating hospitals nationwide were collected. There were no significant changes in the ratio of targeted species among all studied isolates. *E. coli* (47%, *n* = 1053), *K. pneumoniae* (23.4%, *n* = 524), *Salmonella* spp. (10.4%, *n* = 233), and *Enterobacter cloacae* (6.8%, *n* = 152) were the most commonly detected species in blood samples. Notably, the average prevalence rate of *Salmonella* spp. was higher than that of *E. cloacae*, in contrast to other reports.\[[@ref4][@ref5][@ref6][@ref7]\] However, over the entire study period, the number of *Salmonella* spp. declined gradually, whereas that of *E. cloacae* increased continually, accounting for a much larger proportion of the yearly total isolates \[[Table 1](#T1){ref-type="table"}\].

###### 

Distribution and proportion of 2240 Enterobacteriaceae isolates from patients (2004--2014), *n* (%)

  Microorganism       2004--2005 (*n* = 144)   2007--2008 (*n* = 218)   2009--2010 (*n* = 626)   2011--2012 (*n* = 488)   2013--2014 (*n* = 764)   2004--2014 (*n* = 2240)
  ------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ -------------------------
  *E. coli*           45 (31.3)                97 (44.5)                343 (54.8)               248 (50.8)               320 (41.9)               1053 (47.0)
  *Klebsiella* spp.   32 (22.2)                42 (19.3)                165 (26.4)               131 (26.8)               218 (28.5)               588 (26.3)
  *E. cloacae*        9 (6.3)                  12 (5.5)                 40 (6.4)                 29 (5.9)                 62 (8.1)                 152 (6.8)
  *E. aerogenes*      3 (2.1)                  3 (1.4)                  14 (2.2)                 15 (3.1)                 19 (2.5)                 54 (2.4)
  *Salmonella* spp.   46 (31.9)                54 (24.8)                40 (6.4)                 39 (8.0)                 54 (7.1)                 233 (10.4)
  Other               9 (6.3)                  10 (4.9)                 24 (3.8)                 26 (5.3)                 91 (11.9)                160 (7.1)

*E. aerogenes*: *Enterobacter aerogenes*; *E. cloacae*: *Enterobacter cloacae*; *E. coli*: *Escherichia coli*.

Escherichia coli {#sec2-7}
----------------

The nonsusceptibility rates of third- and fourth-generation cephalosporins (except for ceftazidime, CSL, and cefepime) and fluoroquinolones remained high among *E. coli* isolates, although some fluctuations were observed for some antibiotics, with the yearly resistance rates ranging from 53.3% to 81.4%. However, the susceptibility rates of cefazolin, ceftazidime, CSL, and cefepime decreased dramatically\>10% over the 10-year study. Beta-lactamase inhibitor-based combination therapy (including AMC, TZP, MSU, and CSL) showed significantly greater *in vitro* activity than monotherapy (*P* \< 0.01). The same activity was observed for *K. pneumoniae*, albeit to a lesser degree. Carbapenems, moxalactam, tigecycline, and fosfomycin maintained excellent *in vitro* activity against the *E. coli* isolates, with susceptibility rates ranging from 95% to 100% over the 10-year study. Moreover, the nonsusceptibility rate of carbapenems only increased by 0.7--1.3% \[[Figure 1](#F1){ref-type="fig"}\].

![Rates of β-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*, imipenem-resistant Gram-negative bacteria from blood during the period 2004--2014.](CMJ-130-2050-g001){#F1}

The detection rates of ESBL-positive *E. coli* isolates were extremely high and reached a plateau at 58.4--76.3% of all *E. coli* isolates. Compared with cefotaxime and ceftriaxone, ceftazidime maintained better activity against ESBL-positive isolates. However, there was a sharp decrease in the susceptibility rate for ceftazidime from 48.4% to 25.7% over the 10-year study. Moreover, CSL showed decreased efficacy against ESBL-positive *E. coli* isolates, with fluctuations during 2011--2012, and the susceptibility rate dropped from 83.9% to 62.6% over 10 years. Carbapenems, moxalactam, amikacin, and tigecycline maintained excellent *in vitro* efficacy against ESBL-positive *E. coli* isolates \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].

![Susceptibility rates of extended-spectrum β-lactamase- producing *Escherichia coli* isolates to tested antimicrobial agents from blood during the period of 2004--2014.](CMJ-130-2050-g002){#F2}

***Klebsiella*** spp. {#sec2-8}
---------------------

The antimicrobial profiles of *Klebsiella* spp. were similar to those of *E. coli*; however, *Klebsiella* spp. isolates displayed higher susceptibility rates to β-lactam agents than *E. coli* isolates. Notably, over the 10-year period, susceptibility rates to ceftazidime, TZP, and CSL decreased dramatically by 12.8%, 16.2%, and 22.7%, respectively, among *K. pneumoniae* isolates. Among all tested agents,\>90% of *K. pneumoniae* isolates were susceptible to moxalactam, carbapenems (except ertapenem 88.3% susceptible during 2013--2014), tigecycline, fosfomycin, and polymyxin. Importantly, the frequency of occurrence of carbapenem-resistant *K. pneumoniae* increases significantly from 0% in 2004 to 8.9% in 2014, which is higher than the nationwide level for the same period \[6.4% in 2014;\[[@ref8]\] [Figure 1](#F1){ref-type="fig"}\].

The detection rates of ESBL-producing *K. pneumoniae* isolates were lower than those of *E. coli* isolates, with a yearly average rate of 44.1% \[[Figure 1](#F1){ref-type="fig"}\]. There was a pronounced decrease in the *in vitro* activity of CSL over the study period, with susceptibility rates decreasing from 90.9% in 2004 to 51.9% in 2014. Over the 10-year study period, carbapenems showed good activity against ESBL-producing *K. pneumoniae* (\>90.9% susceptible). Amikacin showed increased *in vitro* activity against these isolates, with susceptibility rates increasing from 77.3% in 2004 to 90.9% in 2014. Compared with *E. coli*, imipenem, amikacin, and tigecycline showed relatively lower *in vitro* activity against *K. pneumoniae*, whereas fluoroquinolones displayed much better efficacy against *K. pneumoniae* than *E. coli*. Moxalactam and polymyxins maintained good potency against *K. pneumoniae*, inhibiting\>90% of ESBL-producing isolates. The antimicrobial patterns of Klebsiella oxytoca were similar to those of *K. pneumoniae* \[data not shown and [Figure 3](#F3){ref-type="fig"}\].

![Susceptibility rates of extended-spectrum β-lactamase- producing *Klebsiella pneumoniae* isolates to tested antimicrobial agents from blood during the period of 2004--2014.](CMJ-130-2050-g003){#F3}

***Enterobacter*** spp. {#sec2-9}
-----------------------

During the study period, the total isolation rate of *E. cloacae* was much higher than that of *Enterobacter aerogenes* (6.8% versus 2.4%). Due to the low number (\<10 strains) of tested isolates, the antimicrobial profiles were not determined for both 2004--2005 and 2007--2008. Annual susceptibility rates to tested antimicrobial agents for *E. cloacae* were generally lower than those for *E. aerogenes* during 2009--2010 and 2011--2012, similar to other previous studies in China.\[[@ref9]\] Over the three 1-year consecutive periods (2009--2010, 2011--2012, and 2013--2014), high resistance rates for β-lactam agents (except for carbapenems) were uniformly observed in *E. cloacae* and *E. aerogenes*. Carbapenems, moxalactam, amikacin, tigecycline, and fosfomycin displayed acceptable *in vitro* activity against *E. cloacae* and *E. aerogenes*, with the susceptibility rates of \>75%. Notably, resistance to carbapenems tended to increase in *E. aerogenes*, particularly for ertapenem (from 0% in 2009--2010 to 15.8% in 2013--2014), with MIC~90~ increased from 0.25 to 4 mg/L. The same trend was observed for *E. cloacae*, but to a lesser degree. During 2013--2014, polymyxins (including polymyxin B and colistin) exhibited prominent *in vitro* activity against *E. aerogenes* isolates, with susceptibility rates of \>90%. In contrast, polymyxins showed much lower *in vitro* activity against *E. cloacae* (\<68.3% susceptible).

***Salmonella*** spp. {#sec2-10}
---------------------

*Salmonella* spp. were the third most commonly isolated organisms. Unlike other species within the Enterobacteriaceae family, most tested antimicrobial agents exhibited strong *in vitro* activity against *Salmonella* spp. Among β-lactam agents,\>90% of the isolates were susceptible to TZP, CSL, ceftazidime, cefepime, moxalactam, and carbapenems. Amikacin, tigecycline, and fosfomycin showed strong *in vitro* activity against *Salmonella* spp. Over the 10-year study, only one strain was found to be resistant to carbapenems, and no tigecycline-resistant *Salmonella* spp. were found. Interestingly, there were no significant changes in the resistance rates for fluoroquinolones (\<10% throughout the collection period); however, a large proportion of *Salmonella* spp. (48.7--83.3%) showed intermediate resistance to fluoroquinolones.

***Citrobacter*** spp., ***Serratia*** spp., ***Morganella*** spp., and ***Proteus*** spp. {#sec2-11}
------------------------------------------------------------------------------------------

There were low isolation rates of *Citrobacter* spp., *Serratia* spp., *Morganella* spp., and *Proteus* spp. in this study. The antimicrobial profiles of these species to tested antibiotics are shown in Supplementary Tables [1](#T2){ref-type="table"}--[6](#T7){ref-type="table"}. The third- and fourth-generation cephalosporins showed good *in vitro* activity against *Serratia* spp. and *Morganella* spp., acceptable *in vitro* activity against *Proteus* spp., and low *in vitro* activity against *Citrobacter* spp. The differences in susceptibility to other antibiotics were typically large. Moxalactam and carbapenems showed relatively superior *in vitro* potency compared with other tested antibiotics.

###### 

Antimicrobial susceptibility profiles of *E. coli* from blood in mainland China during the period 2004--2014

  Antibiotics         2004--2005 (*n* = 45)   2007--2008 (*n* = 97)   2009--2010 (*n* = 343)   2011--2012 (*n* = 248)   2013--2014 (*n* = 320)                                                                                                                
  ------------------- ----------------------- ----------------------- ------------------------ ------------------------ ------------------------ ------- ------- ------ ------- ------- ------- ------ ------- ------- ------- ------ ------- ------- ------- ------
  Amoxicillin\*       \>256                   \>256                   11.1                     88.9                     \>256                    \>256   7.2     90.7   \>256   \>256   8.2     91.5   ND      ND      ND      ND     ND      ND      ND      ND
  AMC                 16                      32                      35.6                     26.7                     16                       32      27.8    38.1   \>256   \>256   68.2    13.4   ND      ND      ND      ND     ND      ND      ND      ND
  Piperacillin        \>256                   \>256                   15.6                     82.2                     \>256                    \>256   11.3    78.4   \>256   \>256   14.3    74.1   256     \>256   12.5    74.6   \>256   \>256   15.6    72.8
  TZP                 4                       16                      95.6                     0.0                      8                        32      87.6    3.1    8       32      93.6    5.0    2       16      90.3    5.6    2       16      90.3    5.6
  Mezlocillin^†^      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     256     \>256   16.6    72.3   256     \>256   14.4    71.8   \>256   \>256   15.3    74.7
  MSU^†^              ND                      ND                      ND                       ND                       ND                       ND      ND      ND     32      128     42.0    11.7   16      64      50.8    8.1    32      128     48.8    11.3
  Cefazolin           \>256                   \>256                   28.9                     68.9                     \>256                    \>256   16.5    81.4   256     \>256   20.1    76.4   \>256   \>256   18.1    78.2   \>256   \>256   18.8    70.6
  Cefuroxime          \>256                   \>256                   25.1                     71.1                     \>256                    \>256   21.6    74.2   \>256   \>256   19.2    72.9   \>256   \>256   22.6    76.6   \>256   \>256   34.4    64.4
  Ceftriaxone         4                       16                      31.1                     68.9                     64                       \>256   23.7    74.2   \>256   \>256   27.4    72.0   \>256   \>256   22.6    76.6   \>256   \>256   34.4    64.4
  Cefotaxime          16                      256                     26.7                     71.1                     ND                       ND      ND      ND     1       8       27.7    72.0   64      \>256   23.8    75.8   64      \>256   37.2    62.8
  Ceftazidime         1                       32                      73.3                     15.6                     2                        32      72.2    23.7   32      \>256   65.3    30.9   4       64      52.4    38.7   1       64      61.3    34.1
  Cefoperazone^‡^     64                      \>256                   42.2                     53.3                     128                      \>256   23.7    72.2   64      \>256   29.2    65.3   128     \>256   26.2    64.1   128     \>256   38.1    60.3
  CSL                 4                       32                      88.9                     4.4                      8                        32      76.3    0.0    1       64      69.1    11.7   4       16      90.3    5.2    8       32      75.0    9.4
  Cefepime            1                       32                      55.6                     24.4                     8                        64      35.1    35.1   128     \>256   40.2    32.4   4       32      24.6    42.7   4       64      45.9    37.8
  Aztreonam           ND                      ND                      ND                       ND                       ND                       ND      ND      ND     16      64      52.2    38.8   16      128     41.5    52.0   8       256     47.8    44.4
  Moxalactam          0.125                   2                       97.8                     2.2                      0.25                     1       95.9    2.1    4       64      95.0    0.0    0.25    1       95.6    0.8    0.25    2       96.3    1.3
  Imipenem            0.062                   0.125                   100.0                    0.0                      0.062                    0.125   100.0   0.0    4       128     100.0   0.0    0.062   0.125   99.2    0.8    0.125   0.125   98.8    1.3
  Meropenem           ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.25    1       99.4    0.3    0.016   0.031   98.8    0.4    0.031   0.062   98.4    1.6
  Panipenem^§^        ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.125   0.125   99.1    0.6    0.125   0.125   98.4    0.8    0.125   0.25    98.8    1.3
  Ertapenem           ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.62    0.125   95.6    2.3    0.016   0.5     95.2    2.8    0.016   0.25    98.1    1.3
  Gentamycin          32                      128                     31.1                     64.4                     64                       256     35.1    63.9   0.031   0.031   37.0    62.4   16      128     44.8    52.8   4       128     50.0    49.4
  Amikacin            1                       32                      86.7                     8.9                      2                        64      85.6    11.3   0.16    0.25    94.2    4.1    2       8       93.5    6.0    2       4       96.6    3.1
  Tetracycline        ND                      ND                      ND                       ND                       ND                       ND      ND      ND     32      128     18.4    80.8   128     256     30.2    69.8   128     256     25.0    74.1
  Tigecycline^\|\|^   ND                      ND                      ND                       ND                       ND                       ND      ND      ND     128     256     99.7    0.3    0.25    1       100.0   0.0    0.25    0.5     100.0   0.0
  Ciprofloxacin       16                      64                      31.1                     66.7                     32                       128     17.5    82.5   4       16      31.5    67.9   16      64      32.3    65.7   16      128     38.1    61.3
  Levofloxacin        8                       32                      33.3                     55.6                     16                       32      19.6    72.2   0.25    0.5     34.1    61.2   8       32      34.3    56.0   8       32      38.1    55.6
  Nitrofurantoin      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     128     256     90.4    4.1    8       64      81.9    6.9    16      64      84.7    4.7
  Fosfomycin          ND                      ND                      ND                       ND                       ND                       ND      ND      ND     8       32      93.3    4.7    0.25    128     89.1    6.0    0.5     4       94.7    4.7
  Polymyxin B^¶^      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     ND      ND      ND      ND     ND      ND      ND      ND     1       1       97.5    0.2
  Colistin^¶^         ND                      ND                      ND                       ND                       ND                       ND      ND      ND     ND      ND      ND      ND     ND      ND      ND      ND     0.5     0.5     97.5    0.2

\*The breakpoint of amoxicillin is used as that of ampicillin (S≦8 mg/L; R≦32 mg/L); ^†^The breakpoint of mezlocillin and mezlocillin/sulbactam is used as that of piperacillin (S≦16 mg/L; R≦128 mg/L); ^‡^The breakpoint of cefoperazone is used as that of cefoperazonesulbactam (S≦16 mg/L; R≦64 mg/L); ^§^The breakpoint of panipenem is used as that of imipenem (S≦1 mg/L; R≦4 mg/L); ^‖^The breakpoint of tigecycline is according to FDA (S≦2 mg/L; R≦8 mg/L); ^¶^The breakpoint of polymyxin E and colistin is according to EUCAST (S≦2 mg/L; R≦2 mg/L). ND: No detection; AMC: Amoxicillinclavulanic acid; TZP: Piperacillintazobactam; MSU: Mezlocillinsulbactam; CSL: Cefoperazonesulbactam; FDA: Food and Drug Administration; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).

###### 

Antimicrobial susceptibility profiles of *K. pneumoniae* from blood in mainland China during the period 2004--2014

  Antibiotics      2004--2005 (*n* = 29)   2007--2008 (*n* = 36)   2009--2010 (*n* = 158)   2011--2012 (*n* = 122)   2013--2014 (*n* = 179)                                                                                                              
  ---------------- ----------------------- ----------------------- ------------------------ ------------------------ ------------------------ ------- ------- ------ ------- ------- ------ ------- ------- ------- ------ ------ ------- ------- ------ ------
  Amoxicillin      \>256                   \>256                   0.0                      100.0                    \>256                    \>256   2.8     0.0    \>256   \>256   0.0    100.0   ND      ND      ND     ND     ND      ND      ND     ND
  AMC              16                      128                     34.5                     27.6                     16                       32      47.2    16.7   4       32      72.8   14.6    ND      ND      ND     ND     ND      ND      ND     ND
  Piperacillin     \>256                   \>256                   20.7                     65.5                     256                      \>256   41.7    55.6   64      \>256   45.6   47.5    64      \>256   45.9   48.4   256     \>256   44.1   53.1
  TZP              4                       16                      100.0                    0.0                      4                        16      88.9    0.0    2       64      87.3   10.1    2       64      83.6   9.8    4       \>256   83.8   13.4
  Mezlocillin      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     64      \>256   45.6   47.5    128     \>256   45.9   50.0   256     \>256   44.1   53.6
  MSU              ND                      ND                      ND                       ND                       ND                       ND      ND      ND     16      128     65.2   13.3    16      128     57.4   14.8   16      256     57.0   21.8
  Cefazolin        \>256                   \>256                   24.1                     75.9                     256                      \>256   38.9    61.1   16      \>256   48.1   50.6    32      \>256   46.7   51.6   128     \>256   41.3   55.9
  Cefuroxime       \>256                   \>256                   27.6                     72.4                     \>256                    \>256   41.7    55.6   16      \>256   49.4   48.1    32      \>256   48.4   50.8   256     \>256   46.9   51.4
  Ceftriaxone      64                      128                     27.6                     72.4                     8                        256     41.7    55.6   0.125   256     53.8   46.2    0.25    256     52.5   46.7   16      \>256   48.0   52.0
  Cefotaxime       32                      128                     24.1                     72.4                     ND                       ND      ND      ND     0.25    256     52.5   45.6    0.5     128     52.5   46.7   16      \>256   47.5   52.0
  Ceftazidime      4                       16                      75.9                     17.2                     2                        64      63.9    41.7   0.5     64      69.0   24.7    0.5     64      73.0   22.1   1       128     63.1   35.2
  Cefoperazone     128                     256                     31.0                     65.5                     32                       \>256   44.4    50.0   1       \>256   54.4   40.5    4       \>256   54.1   39.3   32      \>256   49.7   49.2
  CSL              4                       8                       93.1                     3.4                      4                        32      83.3    5.6    1       64      79.1   11.4    2       32      89.3   5.7    4       256     70.4   21.2
  Cefepime         4                       16                      44.8                     27.6                     1                        32      50.0    30.6   0.125   32      68.4   21.5    0.25    32      66.4   17.2   1       64      56.4   31.3
  Aztreonam        ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.125   128     68.4   27.8    0.25    128     66.4   31.1   1       256     56.4   39.1
  Moxalactam       0.25                    2                       93.1                     3.4                      0.125                    0.5     97.2    2.8    0.25    1       96.8   2.5     0.125   2       94.3   0.8    0.25    8       89.9   8.9
  Imipenem         0.25                    0.5                     100.0                    0.0                      0.062                    0.125   100.0   0.0    0.125   0.125   99.4   0.6     0.125   0.25    98.4   1.6    0.125   2       89.4   8.9
  Meropenem        ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.016   0.031   99.4   0.6     0.016   0.031   96.7   3.3    0.031   1       89.9   10.1
  Panipenem        ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.062   0.125   98.7   0.6     0.125   0.125   95.9   3.3    0.125   2       89.4   10.1
  Ertapenem        ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.012   0.25    97.5   1.9     0.008   0.5     95.1   4.1    0.031   4       88.3   11.2
  Gentamycin       32                      \>256                   44.8                     55.2                     1                        32      61.1    16.7   32      128     65.8   33.5    0.5     128     67.2   31.1   1       128     66.5   33.0
  Amikacin         1                       \>256                   82.8                     17.2                     1                        4       88.9    11.1   2       8       91.1   7.0     1       2       93.4   6.6    2       4       92.2   7.8
  Tetracycline     ND                      ND                      ND                       ND                       ND                       ND      ND      ND     128     256     57.0   38.0    4       256     54.1   42.6   8       256     48.6   43.0
  Minocycline      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     4       32      69.0   17.7    2       32      68.9   25.4   4       64      59.2   26.8
  Tigecycline      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.25    0.5     98.1   1.9     0.5     2       91.8   3.3    1       2       91.1   4.5
  Ciprofloxacin    2                       128                     48.3                     48.3                     0.25                     128     41.7    33.3   16      128     69.4   27.8    0.031   64      73.8   24.6   0.125   32      68.7   26.3
  Levofloxacin     2                       64                      55.2                     37.9                     0.25                     32      69.4    27.8   8       32      69.4   19.4    0.062   16      77.0   22.1   0.25    16      72.6   20.7
  Nitrofurantoin   ND                      ND                      ND                       ND                       ND                       ND      ND      ND     8       32      38.6   24.7    64      256     44.3   40.2   128     256     15.1   71.5
  Fosfomycin       ND                      ND                      ND                       ND                       ND                       ND      ND      ND     0.25    8       93.0   6.3     4       64      90.2   6.6    8       64      92.2   5.0
  Polymyxin B      ND                      ND                      ND                       ND                       ND                       ND      ND      ND     ND      ND      ND     ND      ND      ND      ND     ND     1       1       98.3   1.7
  Colistin         ND                      ND                      ND                       ND                       ND                       ND      ND      ND     ND      ND      ND     ND      ND      ND      ND     ND     0.5     1       98.9   1.1

*K. pneumoniae*: *Klebsiella pneumoniae*; ND: No detection; AMC: Amoxicillin-clavulanic acid; TZP: Piperacillin-tazobactam; MSU: Mezlocillin-sulbactam; CSL: Cefoperazone-sulbactam; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).

###### 

Antimicrobial susceptibility profiles of *E. cloacae* from blood in mainland China during the period 2004--2014

  Antibiotics     2009--2010 (*n* = 40)   2011--2012 (*n* = 29)   2013--2014 (*n* = 62)                                                                 
  --------------- ----------------------- ----------------------- ----------------------- ------- ------- ------- ------ ------- ------- ------- ------ ------
  Amoxicillin     \>256                   \>256                   0.0                     100.0   ND      ND      ND     ND      ND      ND      ND     ND
  AMC             32                      64                      5.0                     90.0    ND      ND      ND     ND      ND      ND      ND     ND
  Piperacillin    16                      \>256                   52.5                    45.0    128     \>256   24.1   65.5    8       \>256   58.1   30.6
  TZP             2                       \>256                   72.5                    20.0    4       256     72.4   13.8    4       128     75.8   12.9
  Mezlocillin     16                      \>256                   42.5                    50.0    128     \>256   27.6   62.1    8       \>256   58.1   30.6
  MSU             8                       128                     57.5                    30.0    32      128     41.4   17.2    8       128     66.1   11.3
  Cefazolin       256                     \>256                   0.0                     100.0   \>256   \>256   0.0    100.0   \>256   \>256   1.6    98.4
  Cefuroxime      64                      \>256                   37.5                    55.0    \>256   \>256   17.2   75.9    64      \>256   41.9   53.2
  Ceftriaxone     8                       256                     42.5                    57.5    64      256     27.6   72.4    0.5     \>256   54.8   45.2
  Cefotaxime      16                      256                     45.0                    55.0    64      256     27.6   72.4    0.5     \>256   56.5   43.5
  Ceftazidime     8                       256                     47.5                    47.5    32      256     31.0   69.0    0.5     256     62.9   33.9
  Cefoperazone    4                       \>256                   62.5                    35.0    64      \>256   41.4   55.2    2       \>256   66.1   27.4
  CSL             4                       128                     75.0                    20.0    8       64      62.1   20.7    1       128     75.8   17.7
  Cefepime        0.062                   32                      67.5                    20.0    4       32      48.3   34.5    0.062   16      83.9   12.9
  Aztreonam       8                       \>256                   45.0                    50.0    32      256     41.4   58.6    0.125   128     67.7   29.0
  Moxalactam      0.25                    32                      75.0                    12.5    0.25    128     79.3   13.8    0.25    32      75.8   9.7
  Imipenem        0.125                   0.25                    100.0                   0.0     0.25    1       93.1   6.9     0.5     2       88.7   4.8
  Meropenem       0.031                   0.062                   100.0                   0.0     0.031   1       93.1   6.9     0.031   1       91.9   4.8
  Panipenem       0.125                   0.25                    100.0                   0.0     0.125   4       82.8   13.8    0.5     4       85.5   11.3
  Ertapenem       0.062                   1                       82.5                    5.0     0.125   2       72.4   20.7    0.062   2       83.9   12.9
  Gentamycin      1                       256                     62.5                    37.5    0.5     128     65.5   34.5    0.5     64      87.1   12.9
  Amikacin        2                       16                      92.5                    7.5     1       8       93.1   6.9     2       4       98.4   1.6
  Tetracycline    4                       256                     60.0                    40.0    8       256     55.2   37.9    4       256     67.7   24.2
  Tigecycline     0.5                     2                       97.5                    2.5     0.5     2       93.1   3.4     1       2       95.2   1.6
  Ciprofloxacin   0.125                   16                      47.5                    22.5    0.25    16      37.9   41.4    0.062   1       56.5   17.7
  Levofloxacin    0.062                   4                       52.5                    22.5    0.5     32      34.5   27.6    0.25    2       50.0   14.5
  Fosfomycin      4                       32                      97.5                    2.5     4       32      93.1   6.9     8       32      95.2   3.2
  Polymyxin B     ND                      ND                      ND                      ND      ND      ND      ND     ND      2       \>256   66.1   33.9
  Colistin        ND                      ND                      ND                      ND      ND      ND      ND     ND      1       256     67.7   32.3

*E. cloacae*: *Enterobacter cloacae*; ND: No detection; AMC: Amoxicillin-clavulanic acid; TZP: Piperacillin-tazobactam; MSU: Mezlocillin-sulbactam; CSL: Cefoperazone-sulbactam; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).

###### 

Antimicrobial susceptibility profiles of *Enterobacter aerogenes* from blood in mainland China during the period 2004--2014

  Antibiotics     2009--2010 (*n* = 14)   2011--2012 (*n* = 15)   2013--2014 (*n* = 19)                                                                 
  --------------- ----------------------- ----------------------- ----------------------- ------- ------- ------- ------ ------ ------- ------- ------- -------
  Amoxicillin     \>256                   \>256                   0.0                     100.0   ND      ND      ND     ND     ND      ND      ND      ND
  AMC             32                      32                      0.0                     92.9    ND      ND      ND     ND     ND      ND      ND      ND
  Piperacillin    16                      \>256                   57.1                    42.9    16      256     60.0   20.0   256     \>256   42.1    52.6
  TZP             4                       8                       92.9                    7.1     16      128     53.3   13.3   16      \>256   52.6    36.8
  Mezlocillin     16                      \>256                   50.0                    42.9    16      \>256   53.3   13.3   64      \>256   42.1    47.4
  MSU             8                       128                     57.1                    35.7    16      64      66.7   6.7    16      256     52.6    36.8
  Cefazolin       64                      \>256                   0.0                     85.7    16      \>256   0.0    93.3   \>256   \>256   0.0     100.0
  Cefuroxime      8                       \>256                   50.0                    50.0    32      \>256   46.7   53.3   128     \>256   36.8    57.9
  Ceftriaxone     0.125                   \>256                   50.0                    50.0    0.5     256     60.0   40.0   16      \>256   42.1    57.9
  Cefotaxime      0.125                   256                     50.0                    50.0    0.5     256     60.0   40.0   16      \>256   47.4    52.6
  Ceftazidime     0.25                    16                      64.3                    35.7    1       64      60.0   40.0   16      128     47.4    52.6
  Cefoperazone    0.25                    \>256                   57.1                    42.9    1       \>256   86.7   13.3   128     \>256   47.4    52.6
  CSL             0.125                   64                      57.1                    35.7    2       64      86.7   13.3   4       128     52.6    36.8
  Cefepime        0.031                   32                      57.1                    42.9    0.125   16      86.7   13.3   0.5     256     52.6    36.8
  Aztreonam       0.062                   64                      57.1                    42.9    0.5     64      60.0   40.0   16      256     42.1    52.6
  Moxalactam      0.25                    2                       100.0                   0.0     0.5     16      86.7   6.7    0.5     32      84.2    10.5
  Imipenem        0.125                   0.125                   100.0                   0.0     0.125   0.5     93.3   6.7    1       2       78.9    10.5
  Meropenem       0.016                   0.031                   100.0                   0.0     0.016   0.125   93.3   6.7    0.062   0.25    89.5    5.3
  Panipenem       0.125                   0.125                   100.0                   0.0     0.125   0.25    93.3   6.7    0.25    1       89.5    10.5
  Ertapenem       0.062                   0.25                    100.0                   0.0     0.062   1       93.3   6.7    0.25    4       78.9    15.8
  Gentamycin      0.5                     2                       92.9                    7.1     0.5     1       93.3   6.7    1       64      78.9    21.1
  Amikacin        1                       2                       92.9                    7.1     1       2       93.3   6.7    2       4       100.0   0.0
  Tetracycline    2                       32                      78.6                    14.3    4       32      73.3   20.0   2       128     84.2    15.8
  Tigecycline     0.5                     1                       100.0                   0.0     0.5     4       80.0   0.0    1       1       94.7    5.3
  Ciprofloxacin   0.125                   2                       42.9                    28.6    0.125   64      46.7   26.7   0.016   32      78.9    15.8
  Levofloxacin    0.25                    2                       42.9                    28.6    0.25    8       46.7   26.7   0.062   16      73.7    15.8
  Fosfomycin      8                       8                       100.0                   0.0     4       16      93.3   0.0    8       256     84.2    15.8
  Polymyxin B     ND                      ND                      ND                      ND      ND      ND      ND     ND     1       1       89.5    10.5
  Colistin        ND                      ND                      ND                      ND      ND      ND      ND     ND     0.5     1       94.7    5.3

ND: No detection; AMC: Amoxicillin-clavulanic acid; TZP: Piperacillin-tazobactam; MSU: Mezlocillin-sulbactam; CSL: Cefoperazone-sulbactam; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).

###### 

Antimicrobial susceptibility profiles of *Salmonella* spp. from blood in mainland China during the period 2004--2014

  Antibiotics      2004--2005 (*n* = 46)   2007--2008 (*n* = 54)   2009--2010 (*n* = 40)   2011--2012 (*n* = 39)   2013--2014 (*n* = 54)                                                                                                               
  ---------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ------- ------- ----- ------- ------- ------- ------ ------- ------- ------- ------ ------- ------- ------- ------
  Amoxicillin      1                       512                     84.8                    15.2                    1                       512     59.3    0.0   4       512     60.0    40.0   ND      ND      ND      ND     ND      ND      ND      ND
  AMC              1                       4                       93.5                    4.3                     1                       8       90.7    0.0   4       8       97.5    0.0    ND      ND      ND      ND     ND      ND      ND      ND
  Piperacillin     2                       16                      95.7                    4.3                     4                       512     59.3    0.3   8       128     57.5    17.5   2       128     69.2    30.8   4       512     57.4    38.9
  TZP              2                       2                       100.0                   0.0                     2                       8       94.4    0.0   2       4       100.0   0.0    2       8       94.9    5.1    4       16      94.4    3.7
  Mezlocillin      ND                      ND                      ND                      ND                      ND                      ND      ND      ND    8       128     57.5    22.5   4       64      69.2    7.7    8       512     57.4    40.7
  MSU              ND                      ND                      ND                      ND                      ND                      ND      ND      ND    4       16      92.5    0.0    4       32      87.2    5.1    8       64      64.8    1.9
  Cefazolin        2                       2                       91.3                    8.7                     2                       64      85.2    0.1   2       2       90.0    2.5    2       64      87.2    12.8   2       512     70.4    22.2
  Cefuroxime       4                       8                       87.0                    4.3                     4                       16      77.8    0.1   8       8       95.0    0.0    8       16      87.2    12.8   8       256     75.9    16.7
  Ceftriaxone      0.062                   0.062                   93.5                    6.5                     0.062                   0.25    90.7    0.1   0.062   0.062   100.0   0.0    0.062   0.125   94.9    5.1    0.125   16      87.0    13.0
  Cefotaxime       0.062                   0.062                   93.5                    6.5                     ND                      ND      ND      ND    0.062   0.125   100.0   0.0    0.125   0.25    94.9    5.1    0.125   16      85.2    11.1
  Ceftazidime      0.25                    0.25                    97.8                    2.2                     0.25                    0.5     100.0   0.0   0.25    0.25    100.0   0.0    0.25    0.25    94.9    5.1    0.25    1       90.7    9.3
  Cefoperazone     0.5                     2                       95.7                    2.2                     1                       64      81.5    0.2   0.5     8       100.0   0.0    0.5     8       94.9    5.1    1       128     81.5    13.0
  CSL              0.5                     1                       78.3                    21.7                    0.5                     16      96.3    0.0   0.5     8       100.0   0.0    0.5     4       94.9    5.1    0.5     16      94.4    1.9
  Cefepime         0.031                   0.031                   97.8                    0.0                     0.031                   0.25    98.1    0.0   0.031   0.062   100.0   0.0    0.062   0.125   94.9    5.1    0.062   2       90.7    7.4
  Aztreonam        ND                      ND                      ND                      ND                      ND                      ND      ND      ND    0.031   0.125   100.0   0.0    0.062   0.25    94.9    5.1    0.125   4       90.7    9.3
  Moxalactam       0.062                   0.062                   95.7                    2.2                     0.062                   0.125   98.1    0.0   0.062   0.125   100.0   0.0    0.062   0.125   97.4    0.0    0.125   0.125   98.1    1.9
  Imipenem         0.25                    0.25                    100.0                   0.0                     0.062                   0.062   100.0   0.0   0.125   0.125   100.0   0.0    0.125   0.25    100.0   0.0    0.125   0.25    98.1    1.9
  Meropenem        ND                      ND                      ND                      ND                      ND                      ND      ND      ND    0.016   0.016   100.0   0.0    0.016   0.031   97.4    0.0    0.016   0.031   98.1    1.9
  Panipenem        ND                      ND                      ND                      ND                      ND                      ND      ND      ND    0.062   0.125   100.0   0.0    0.062   0.25    97.4    0.0    0.125   0.25    98.1    1.9
  Ertapenem        ND                      ND                      ND                      ND                      ND                      ND      ND      ND    0.031   0.008   100.0   0.0    0.016   0.016   97.4    2.6    0.008   0.016   98.1    1.9
  Gentamycin       0.062                   0.5                     89.1                    10.9                    0.5                     64      70.4    0.3   0.5     16      87.5    12.5   0.25    1       89.7    7.7    0.5     32      87.0    13.0
  Amikacin         0.25                    1                       100.0                   0.0                     1                       2       98.1    0.0   1       2       100.0   0.0    0.5     1       97.4    2.6    1       2       96.3    3.7
  Tetracycline     ND                      ND                      ND                      ND                      ND                      ND      ND      ND    4       128     75.0    25.0   1       64      79.5    17.9   2       128     75.9    20.4
  Tigecycline      ND                      ND                      ND                      ND                      ND                      ND      ND      ND    0.125   1       100.0   0.0    0.5     0.5     100.0   0.0    0.5     1       100.0   0.0
  Ciprofloxacin    0.125                   0.125                   30.4                    0.0                     0.25                    0.5     16.7    0.1   0.125   0.125   35.0    7.5    0.125   0.25    48.7    2.6    0.125   0.5     25.9    5.6
  Levofloxacin     0.5                     0.5                     30.4                    2.2                     0.5                     1       20.4    0.1   0.5     1       27.5    7.5    0.25    1       38.5    2.6    0.25    1       27.8    3.7
  Nitrofurantoin   ND                      ND                      ND                      ND                      ND                      ND      ND      ND    16      128     57.5    20.0   16      128     64.1    10.3   64      128     40.7    31.5
  Fosfomycin       ND                      ND                      ND                      ND                      ND                      ND      ND      ND    0.125   16      100.0   0.0    4       32      100.0   0.0    0.25    64      98.1    1.9

ND: No detection; AMC: Amoxicillin-clavulanic acid; TZP: Piperacillin-tazobactam; MSU: Mezlocillin-sulbactam; CSL: Cefoperazone-sulbactam; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).

###### 

Antimicrobial susceptibility profiles of *Citrobacter* spp., *Serratia* spp., *Morganella* spp., and *Proteus* spp. from blood in mainland China during the period 2004--2014

  Antibiotics      *Citrobacter* spp. (*n* = 22)   *Serratia* spp. (*n* = 86)   *Morganella* spp. (*n* = 22)   *Proteus* spp. (*n* = 30)                                                                                         
  ---------------- ------------------------------- ---------------------------- ------------------------------ --------------------------- ------- ------- ------ ------ ------- ------- ------- ------- ------- ------- ------- ------
  Amoxicillin      \>256                           \>256                        0.0                            100.0                       64      \>256   10.0   90.0   256     \>256   0.0     100.0   \>256   \>256   14.3    85.7
  AMC              64                              128                          33.3                           66.7                        64      128     20.0   80.0   128     256     0.0     100.0   4       8       85.7    0.0
  Piperacillin     256                             \>256                        22.7                           63.6                        4       256     74.4   23.3   2       128     77.3    13.6    2       64      75.0    3.6
  TZP              4                               256                          77.3                           13.6                        2       8       96.5   3.5    0.25    0.5     100.0   0.0     0.5     1       100.0   0.0
  Mezlocillin      256                             \>256                        29.4                           58.8                        8       \>256   74.1   21.0   4       128     73.7    21.1    8       128     54.2    25.0
  MSU              64                              128                          41.2                           17.6                        4       64      79.0   12.3   2       16      100.0   0.0     4       8       100.0   0.0
  Cefazolin        \>256                           \>256                        9.1                            90.9                        \>256   \>256   2.3    97.7   256     \>256   0.0     90.9    128     \>256   21.4    64.3
  Cefuroxime       128                             \>256                        27.3                           72.7                        256     \>256   3.5    96.5   32      128     27.3    59.1    256     \>256   35.7    64.3
  Ceftriaxone      128                             \>256                        30.0                           70.0                        0.5     128     69.0   28.6   0.016   2       75.0    25.0    1       256     45.8    54.2
  Cefotaxime       64                              256                          31.8                           68.2                        0.5     128     70.9   27.9   0.031   8       77.3    9.1     4       \>256   50.0    46.4
  Ceftazidime      32                              128                          40.9                           59.1                        0.25    8       88.4   4.7    0.125   16      77.3    13.6    0.062   32      82.1    14.3
  Cefoperazone     64                              \>256                        40.9                           54.5                        2       256     76.7   22.1   1       32      77.3    4.5     4       128     60.7    35.7
  CSL              16                              32                           63.6                           18.2                        1       32      88.4   5.8    1       4       100.0   0.0     1       4       96.4    0.0
  Cefepime         0.25                            8                            54.5                           31.8                        0.125   16      76.7   16.3   0.031   0.062   100.0   0.0     1       16      64.3    14.3
  Aztreonam        16                              256                          35.3                           58.8                        0.125   64      72.8   19.8   0.016   0.5     100.0   0.0     0.5     8       87.5    8.3
  Moxalactam       0.5                             4                            72.7                           13.6                        0.5     4       93.0   4.7    0.125   0.125   100.0   0.0     0.125   0.25    100.0   0.0
  Imipenem         0.125                           0.5                          90.9                           9.1                         0.5     1       90.7   7.0    2       4       40.9    22.7    1       2       64.3    7.1
  Meropenem        0.031                           0.062                        88.2                           11.8                        0.062   0.25    93.8   6.2    0.062   0.125   100.0   0.0     0.062   0.125   100.0   0.0
  Panipenem        0.125                           0.5                          90.0                           10.0                        0.5     2       88.1   8.3    1       2       65.0    10.0    1       2       79.2    4.2
  Ertapenem        0.062                           0.25                         88.2                           11.8                        0.031   0.25    92.6   6.2    0.016   0.031   100.0   0.0     0.016   0.031   100.0   0.0
  Gentamycin       1                               2                            71.4                           23.8                        1       128     77.9   17.4   0.5     128     54.5    27.3    8       \>256   46.4    39.3
  Amikacin         1                               2                            95.5                           4.5                         2       128     81.4   17.4   1       4       100.0   0.0     4       \>256   85.7    14.3
  Tetracycline     2                               256                          58.8                           29.4                        32      128     22.2   64.2   32      64      36.8    47.4    32      64      4.2     91.7
  Tigecycline      0.25                            1                            100.0                          0.0                         2       4       87.7   0.0    2       8       57.9    15.8    2       4       62.5    8.3
  Ciprofloxacin    0.125                           1                            68.2                           31.8                        0.125   4       87.2   8.1    0.5     8       81.8    13.6    4       64      39.3    60.7
  Levofloxacin     0.5                             16                           68.2                           27.3                        0.25    4       86.0   8.1    1       2       90.9    9.1     4       32      39.3    46.4
  Nitrofurantoin   32                              128                          52.9                           17.6                        256     \>256   33.3   65.4   64      128     5.3     42.1    128     128     4.2     58.3
  Fosfomycin       0.25                            0.25                         100.0                          0.0                         8       32      75.3   23.5   256     \>256   26.3    57.9    8       256     66.7    29.2
  Polymyxin B      2                               4                            81.8                           18.2                        ND      ND      ND     ND     ND      ND      ND      ND      ND      ND      ND      ND
  Colistin         2                               2                            100.0                          0.0                         ND      ND      ND     ND     ND      ND      ND      ND      ND      ND      ND      ND

ND: No detection; AMC: Amoxicillin-clavulanic acid; TZP: Piperacillin-tazobactam; MSU: Mezlocillin-sulbactam; CSL: Cefoperazone-sulbactam; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Over the collection periods (2004--2005, 2007--2008, 2009--2010, 2011--2012, 2013--2014), Enterobacteriaceae isolates exhibited distinctively different antimicrobial susceptibilities to tested antibiotics. In this study, β-lactam antibiotics (except for carbapenems) displayed extremely poor *in vitro* activity against the Enterobacteriaceae family with the exception of *Salmonella* spp. Third-generation cephalosporin-resistant isolates were often found to be resistant to fluoroquinolones and aminoglycosides (gentamycin and amikacin) simultaneously. In this 10-year study, 2.1--6.3% of the 2240 Enterobacteriaceae isolates were resistant to these three types of antibiotics (data not shown), corresponding to the results of a European survey over the same period (1.4--19.7%).\[[@ref10]\]

The detection rates of ESBL-producing *E. coli* and *K. pneumoniae* isolates were almost unchanged and remained consistently high over the 10-year study, with yearly total rates of 66.7% (702/1053) and 44.1% (231/524), respectively; these rates were much higher than those of other countries.\[[@ref10][@ref11]\] ESBL production is the main reason for treatment failure of β-lactam antibiotics. According to a previous survey, the CTX-M genotype, associated with the hydrolysis of cefotaxime and ceftriaxone, is the main genotype of ESBLs.\[[@ref12][@ref13]\] This could explain why cefotaxime and ceftriaxone showed much lower *in vitro* efficacy than ceftazidime against ESBLs.

Throughout the study,\[[@ref7]\] a trend toward increased nonsusceptibility rates for carbapenems was observed, especially for *K. pneumoniae* and *E. aerogenes*. During 2013--2014, the nonsusceptibility rates of *K. pneumoniae* and *E. aerogenes* to ertapenem reached up to 11.7% and 21.1%, respectively. Furthermore, carbapenem resistance was generally caused by the production of carbapenemases carried by plasmids, which could be transmitted within species or even from species to species. However, the genes encoding carbapenemases often carry some other resistance factors at the same time, leading to extensively drug-resistant bacteria.\[[@ref14]\] Thus, the problem of carbapenem-resistant Enterobacteriaceae (CRE) has become a major challenge to public health worldwide, resulting in higher mortality rates caused by infections and a lack of reliable treatment.\[[@ref15][@ref16][@ref17][@ref18]\]

In this study, some reviving antibiotics, including fosfomycin and polymyxins, were found to be effective alternative treatments against CRE. Polymyxins displayed strong activity against Enterobacteriaceae, with susceptibility rates of \>90%, except for *E. cloacae* (66.7% susceptible). However, colistin-resistant isolates have emerged globally within the last few years.\[[@ref19][@ref20]\] Recently, a mobile colistin-resistance gene, called *mcr*-1, has been reported in Enterobacteriaceae isolated both from livestock and humans; this gene may compromise treatment with last resort antimicrobial agents (colistin), thereby posing a major threat to public health.\[[@ref21][@ref22]\] According to a survey in Europe, the resistance rate for polymyxins among carbapenem-resistant *K. pneumoniae* isolates is as high as 43%.\[[@ref23]\] In this study, only 6.25% (1/16) of carbapenem-resistant *K. pneumoniae* isolates were found to be resistant to polymyxin B, whereas no isolates were resistant to colistin. This finding may be associated with the rare clinical use of polymyxins in China.

Given the severe condition of AMR among Enterobacteriaceae isolated from blood, precautions must be taken to control the presence of drug-resistance bacteria. A previous study\[[@ref24]\] showed that β-lactamase-producing Gram-negative bacteria are associated with antibiotic use in healthcare settings, antibiotic use in animals, hand hygiene, environmental contamination with antibiotic-resistant bacteria, and travel. Thus, only interdisciplinary collaboration will be able to overcome the latent threat of AMR.

Several approaches could be helpful in this regard. First, professional training and public education should be strengthened. For example, leaflets, posters, and educational courses are needed to emphasize the urgency and seriousness of reducing AMR. Second, antimicrobial prescriptions must be optimized;\[[@ref25]\] the use, misuse, and overuse of antibiotics are major determinants of AMR,\[[@ref24]\] and promoting rational prescribing and proper use of existing antibiotics will be important. Third, governments should implement regulations to contain AMR, such as bans on the use of antibiotic growth promoters in livestock and agriculture. Fourth, better use of surveillance data, including development of comprehensive nationwide surveillance networks and monitoring of trends in AMR, is essential. Finally, the development of new drugs as powerful antimicrobial agents, particularly those that are active against ESBL producers and multidrug-resistant bacteria, is urgently needed to replace ineffective drugs; however, antibiotics show little opportunity compared with other therapeutic categories owing to the development bottleneck in new scientific breakthroughs and lack of economic incentives.\[[@ref26]\]

In conclusion, the control of AMR requires interdisciplinary cooperation of medical microbiologists, veterinarians, hospital doctors, microbiology laboratories, and government officials. The increasing AMR in Enterobacteriaceae strains isolated from the blood is still a major problem that should be monitored closely worldwide.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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